ENTRY       D05350                      Drug
NAME        Panitumumab (USAN/INN);
            Panitumumab (genetical recombination) (JAN);
            Vectibix (TN)
PRODUCT     VECTIBIX (Amgen)
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG01917  Receptor tyrosine kinase inhibitor
               DG03162  EGFR inhibitor
REMARK      Therapeutic category: 4291
            ATC code: L01FE02
            Product: D05350<JP/US>
EFFICACY    Antineoplastic, Anti-epidermal growth factor receptor antibody
  DISEASE   Colorectal cancer (KRAS and NRAS wild type) [DS:H00020]
  TYPE      Monoclonal antibody
TARGET      EGFR [HSA:1956] [KO:K04361]
  PATHWAY   hsa04010(1956)  MAPK signaling pathway
            hsa04012(1956)  ErbB signaling pathway
            hsa05200(1956)  Pathways in cancer
INTERACTION  
STR_MAP     map07045  Antineoplastics - protein kinase inhibitors
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FE EGFR (Epidermal Growth Factor Receptor) inhibitors
                 L01FE02 Panitumumab
                  D05350  Panitumumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Panitumumab
                D05350  Panitumumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D05350  Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG01917  Receptor tyrosine kinase inhibitor
                DG03162  EGFR inhibitor
                 D05350  Panitumumab
            Drug classes [BR:br08332]
             Antineoplastic
              DG03162  EGFR inhibitor
               D05350  Panitumumab
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               EGFR family
                EGFR
                 D05350  Panitumumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D05350
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D05350
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D05350
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D05350
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D05350
DBLINKS     CAS: 339177-26-3
            PubChem: 47207035
            NIKKAJI: J2.309.659E
///
